Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID Code: 13752399 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1711877&tp_key=ce7eaa5c39 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonom

Advances Tivic's Development of Non-Invasive VNS Devices Aimed at Treating Inflammatory, Cardiac and Neurologic Disorders Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to current, more invasive treatment options. The data were presented in a poster presentation, titled, "Autonomic,

Tivic Health® Systems, Inc. (NASDAQ:TIVC) ("Tivic Health" or the "Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq"), and is part of the Company's Compliance Plan, as presented to Nasdaq on February 18, 2025. The reverse stock split was approved by the stockholders of the Company at a special meeting of the Company held on January 31, 2025. The reverse stock split will

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team. Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distrib

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID Code: 13752399 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1711877&tp_key=ce7eaa5c39 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonom

Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. "This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," stated Jennifer Ernst, CEO of Tivic Health. "The first prong is the aggressive steps we have taken to improve the economics of the ClearUP product line -- our comme

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)